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Abstract
The current economic crisis in Europe has challenged the basis of the
economic model that currently prevails in much of the industrialised
world. It has revealed a system that is managed not for the benefit of the
people but rather for the corporations and the small elite who lead them,
and which is clearly unsustainable in its present form. Yet, there is a
hidden consequence of this system: an unfolding crisis in health care,
driven by the greed of corporations whose profit-seeking model is also
failing. Proponents of commodifying healthcare simultaneously argue
that the cost of providing care for ageing populations is unaffordable
while working to create demand for their health care products among
those who are essentially healthy. Will healthcare be the next profit-
fuelled investor bubble? In this paper, we call on health professionals to
heed the warnings from the economic crisis and, rather than stand by
while a crisis unfolds, act now to redirect increasingly market-oriented
health systems to serve the common good.
Two crises
On 26th December 1991, the Soviet flag flying over the Kremlin was
lowered for the last time, to be replaced by that of the newly independ-
ent Russia. This symbolised the death of communism as an organising
principle of society in Europe, the end of an experiment that had
begun in St. Petersburg in October 1917.1 No longer would there be
any serious argument about what was the best way to organise socie-
ty, communism or capitalism. Communism was broken and capitalism
was triumphant.2 Yet, twenty years later, it is the capitalist system that
seems broken.3 Mass demonstrations on a scale seen two decades ago
in Prague, Warsaw and Budapest are being replayed on the streets of
Athens, Lisbon, Madrid and Rome. The situation in Western Europe
displays many parallels with the dying days of the communist system.
Just as, in the 1980s, the communist economies stagnated, real
incomes for average families in employment in western Europe have
barely changed since the early 1990s, although now the reality has
been disguised by the availability of cheap credit. Yet neither system
was sustainable. Just as in central Europe in the late 1980s, once the
system began to unravel, it did so very quickly, with politicians rapidly
losing control of events.4,5 In both cases, the policies they pursued
failed, often spectacularly. Then, it was the attempt to reform the sys-
tem from within. Now, it is the policies of austerity, promoted as a
means of tackling the economic crisis, but making things much
worse.6 Suicides are a key indicator of the confidence that the popula-
tion has in its rulers. Yet, suicides are now rising in western Europe
too, reversing the long downward trend that had lasted for several
decades.7  As in the communist period, not everyone is equally affect-
ed. Then the beneficiaries were the nomenklatura, the communist
party elite. Now, it is the 0.001% of the population who head major cor-
porations, earning over 350 times the wages of the average worker.
Just as the nomenklatura had their own Zil lanes in the Soviet Union,
now they use the separate Olympic lanes in London as they speed to
the events they have sponsored using money they have taken from the
general public. There was not always such dominance by a super-rich
aristocracy. For much of the post-war period, the capitalist system ben-
efitted most people, just as in the days following the Russian revolu-
tion, the communist system brought enormous benefits to its people,
introducing universal health care and expanding education to achieve
universal literacy. But both went very badly wrong. In the case of com-
munism, it was the murderous policies pursued by Stalin from the late
1920s.8 In the case of capitalism, it was the laissez faire policies pur-
sued by Thatcher and Reagan in the 1980s.9 What do these systemic
changes mean for the future of health systems in Europe? First, we
trace the rise and fall of market capitalism in Europe and North
America, showing how the major corporations in the financial sector
redefined their roles, abandoning their traditional role of providing
income for savers and supporting small businesses, and taking up
what amounts to reckless gambling with the money of their sharehold-
ers and depositors, all for their own benefit. Then, we will reflect on
how changes in the financial system will affect health care. The pres-
sure to expand markets has moved into basic human needs, creating
bubbles in food and housing. Inevitably when they crash, investors
seek to expand more markets for profiteering. Healthcare is set to
become the next commodity bubble as an increasing number of corpo-
rations enter this sector, moving into the delivery of health care. Like
Significance for public health
In circumstances such as those described in this paper, public health profes-
sionals have a duty to speak out. They can look for inspiration to the
Prussian physician Rudolph Virchow who, while fully aware of the key role
played by lice, drew attention to the social and economic circumstances in
Silesia in the nineteenth century that allowed typhus epidemics to occur.*
Yet, in recent years, too many public health professionals have left the big
decisions to politicians and economists, assuming they must know what they
are doing. But now we know that they do not. A different solution is needed
that prioritises health and social wellbeing. Public health professionals are
as well equipped as anyone to propose it. They might start by looking at how
they can change what is happening in health care and then apply the lessons
more broadly. At least it will be a start.
*Reilly RG, McKee M. 'Decipio': examining Virchow in the context of modern
'democracy'. Public Health 2012;126:303-7.
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the financial institutions, they are rewriting the rules to benefit them-
selves. In this case, they have abandoned their traditional roles of
developing the drugs that people need and treating those who are ill.
They have realised that they cannot make money out of the increasing
numbers of people with multiple complex disorders so instead they
leave them for state systems to pick up their care, all the while com-
plaining about the taxes they pay for those state systems as they strug-
gle with ever more complex patients and fewer resources. They are
redirecting their efforts to persuading those who have nothing wrong
with them that they really need the much more straightforward and
predictable care that they can provide. We conclude with a proposal for
activism to challenge the forces that stand posed to plunder public
health systems for their personal gain at great cost to us all.
The triumph of capitalism
Today, in the world’s economic centres such as Wall Street and the
City of London, regulations that had once held the financial markets in
check are viewed as obsolete. Advances in computing now allow billions
of dollars of shares to be traded in milliseconds. In the 1980s, new types
of traders were recruited, with degrees in maths, physics and engineer-
ing, all trained in the more obscure areas of mathematical theory. 
The financial markets changed profoundly. The original rationale for
a stock market was to raise money to enable companies to grow.
Investors looked for people with clever ideas who they could turn into a
sustained profit stream. They invested for the long term. The same was
true of banks. Local bank managers knew the business people who lived
in their town or city. They were willing to take risks and, in doing so,
provided the capital that allowed large numbers of small and medium
companies to start up and grow, providing local employment and bene-
fitting everyone. But this was to be swept away. Long-term investments
were discarded as those in the financial sector realised that they could
make billions of dollars in an afternoon using ever more complex deriv-
atives; in reality just a form of gambling, albeit for very high stakes and
with other people’s money.10  Bank chief executives asked themselves:
“Why waste money on local branches when we could improve efficien-
cy by centralising banking and making decisions on which companies
to support based on computerised algorithms rather than detailed local
knowledge?” Slowly, the financial system stopped being something that
was there to support ordinary people, as investors, manufacturers, pen-
sioners and savers, but rather a means by which a tiny percentage of
the population could become fabulously rich at other’s expense, using
their money.5 Once, the companies they ran would return most of their
profits to shareholders. No more. Now most of it would go on bonuses
to senior staff. And in many cases these profits were greatly inflated by
outsourcing as much of their workforce as possible, ideally to develop-
ing countries such as India. The heads of these companies had lobbied
hard to ensure the free global movement of goods, services and capital,
but were determined not to extend that to people. After all, if the high-
ly trained workers in developing countries could come to Europe or
America, then they would demand higher wages, something they con-
sidered totally unacceptable. 
The public went along with this. Ordinary people in many parts of
Europe, but even more so in the United States, thought that the system
was benefitting them. They failed to understand what was happening
in the financial markets, but they did not really care. They were able to
get cheap credit to buy a new house and to fill it with consumer goods.
What they failed to realise was that they were not alone in their igno-
rance of what was happening in the financial markets. Few, if any, of
those senior executives who were awarding each other astronomical
rewards had any idea what was happening either. They just thought the
good times would continue forever. But they would not.
Too good to last?
In 2007, it all began to go wrong. Those Americans who had bought
houses with sub-prime loans could no longer repay them. Often to their
amazement, investors in Europe who thought that they had placed their
savings and pension funds in what they thought were safe products in
other countries realised that they were sitting on a pile of worthless
real estate in a remote corner of Arizona. Panic swept through the glob-
al markets. And it continues to do so today. 
The financial crisis was like the tide going out. Only then was it
apparent who was not wearing a swimsuit. It soon became clear that
the Greek economy was built on straw. For years, many people had
struggled to understand what was happening in Greece. How could a
country with such weak infrastructure be doing so well? But of course
it was not. It is now clear that the Greek government was simply mak-
ing up the numbers.11 The same was true for many banks. First there
were the derivatives they had invested in, many of which led to massive
losses. But there were also the bad loans. Those computerised algo-
rithms that had replaced the local knowledge of bank managers had left
them with piles of worthless assets. 
Systematically this approach of reaping gains from reckless invest-
ing has expanded into all domains of public life. Housing was the sec-
tor that led to the current crash. Food then became the next hot com-
modity, following a similar boom-bust cycle, generating massive profits
for investment funds.12 Now investors are beginning to apply these tac-
tics by stealth to healthcare. What are the implications for health sys-
tems, and how should those of us working in public health respond?
The lessons for health care 
The corporate greed that underpinned the financial crisis has impli-
cations for health policy that are too easy to overlook. Some years ago,
major corporations realised that they needed to move beyond the tradi-
tional means of making money, the production of goods that people
would buy, to the provision of services. The problem was that many of
the key services that people depended on, such as health, education,
and social care, were being provided by the state, at least in Western
Europe. The challenge they faced was to transform these services,
which for 50 years had been funded by taxes, based on the ability of cit-
izens to pay, and received on the basis of need. They were owned col-
lectively by the people through the intermediary of the state, and peo-
ple remained safe in the knowledge that they would be there when
needed. They were not seen as an opportunity for private profit. 
To change this, market elites first had to rewrite the rules in their
favour, getting their client governments in North America and Europe
to shape the General Agreement on Trade in Services to their advan-
tage.13 Within the European Union, similar measures were adopted in
relation to the provision of services.14 To get their hands on health and
education services, seen as the main growth areas, the corporations
needed to prise them away from government control. The anticipated
rewards of privatisation were enormous, as they had realised in the
United States where returns on investment in the health sector had
been huge (now accounting for one-fifth of GDP, the highest world-
wide). And health had another benefit. The demand was potentially
unlimited, not least because those who supplied it could themselves
stimulate demand.
Second, the market elites had to overcome resistance from a univer-
sal public system that had enduring popularity and public support. This
involved creating popular discontent, drawing attention to any failings
in the public system, and promoting choice as a value in itself, along-
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side  effectiveness, efficiency, humanity and equity.15 
However, in seeking to unleash a market in health care they faced
some fundamental problems. Some fifty years ago, the Nobel Laureate
Kenneth Arrow described why the market in health care fails.16 The
reasons include the presence of externalities, whereby one person ben-
efits from another receiving health care, especially if they have a con-
tagious disease or a psychosis that may cause them to be violent. There
is also information asymmetry, where the health professional offering
care knows more about what the patient needs than they do them-
selves. But above all there is the problem that those who are in most
need of care are the least able to afford it. In contrast, those who need
care least have plenty of money. This was recognised in the 1920s in
the United States when the insurers Blue Cross and Blue Shield were
created by associations of doctors and hospitals, not because they were
concerned about the ability of people to obtain care, but rather to
ensure that they themselves would be paid for providing it. Given these
well-known market failures, how can the private sector make the prof-
its it sought from health care? The answer is to redefine health care, as
shown in the next section.
The patient paradox
A British general practitioner, Margaret McCartney has recently
described what she terms the Patient Paradox.17 She describes her dif-
ficulties, even in the National Health Service in the United Kingdom,
in getting appropriate care for her patients who really do have illness-
es, and especially the most difficult group, those with mental illness,
while at the same time being cajoled, encouraged, and incentivised to
deliver services, such as ever increasing varieties of unevaluated
screening, to those who are well. Put simply, those with real illnesses
offer little scope for profit by those who have been contracted, in the
British internal health care market, to provide care.
The problem is exemplified at an international level by neglected
tropical diseases. They are neglected for a reason. The reason is that
the pharmaceutical industry cannot see a way of making money out of
them. If these diseases are to be cured, it will not be enough to rely on
the capitalist market.18 Instead, there is a need for intervention by the
state, or states, for example through advance market commitments,
whereby governments agree to share the risk of development.19
However, they are simply symptoms of a wider problem. 
The pharmaceutical industry now realises that it is running out of
ideas that will make it the massive profits it was once used to. These
profits were based on a model that found a common disease, ideally
with its onset about middle age, which would require regular treatment
for years. It found them. They included, among others, high blood pres-
sure, chronic airways disease, diabetes, Parkinson’s Disease, and
depression. But the problem now is that there are no more of these dis-
eases to be found. There are perfectly good treatments for them and
any new treatments can make, at most, a marginal contribution, and
even that is frequently exaggerated by selective reporting and manipu-
lation of clinical trial data.20 These firms could develop antibiotics, but
the problem there is that resistance emerges before expiry of patent
protection, so there is no money to be made.21 Then there is cancer, but
it is not a single disease. The more scientists learn about it, the more
they divide the market into smaller and smaller parts.22 Any new drug
will be effective against tumours in a relatively small number of people.
They will only take it for a short while. The cost per dose will be astro-
nomical. Publicly funded health systems will be reluctant to pay, know-
ing that they will have to reduce existing care for others as a result.23
And the individual patient will, with rare exceptions, be able to pay. The
same is true of drugs for children.24 Who will pay for the necessary test-
ing knowing that the market will be tiny? Instead, the industry has
focused on so-called lifestyle drugs. Anyone watching American televi-
sion could be forgiven for thinking that the entire male population
must have erectile dysfunction. The system of drug production, based
on the free market, is as broken as the financial system and, just like
it, it is far from clear how to fix it. 
But it is not just pharmaceutical companies that face fundamental
problems. So do those corporations moving into the delivery of health
care. Their problems are illustrated by the ageing of populations. Older
people can be very difficult to treat. They do not fit into convenient
boxes with a single disease. They have multiple disorders, necessitat-
ing a complex combination of drugs, many of which may interact with
each other.25 They may have varying degrees of organ failure, with their
liver or kidney function influencing how those drugs are metabolised.
They may have cognitive decline, so that they forget to take their
tablets when they should, leading to unanticipated and potentially
unnecessary admissions to hospital. Fundamentally, they are unpre-
dictable and, as we are constantly told, markets hate uncertainty.
Anyone running a health system for profit will see them as the last peo-
ple they want to deal with. Instead, they want to design simple, proto-
col-driven packages for young people with single diseases, such as
uncomplicated diabetes or asthma, that can be delivered by health
workers with minimum training, or even better, by computerised sys-
tems that take the human touch out of care delivery altogether. 
These examples illustrate the problems that corporations active in
the health sector are facing. To respond, just as the financial sector did
when it realised that its traditional sources of profit were no longer suf-
ficiently lucrative, they must redefine the rules of the game. In the next
section, we examine how they are doing this.
The medical-industrial complex
Back in the 1950s, Eisenhower warned about what he called the mil-
itary industrial complex, whereby a powerful coalition of generals and
chief executives conspired to talk up the threat from the Soviet Union,
exaggerating the so-called ‘missile gap’ and seeing threats where none
existed.26 The goal was not to protect the United States, but instead to
transfer vast sums of money from the federal budget to the coffers of
the corporations, and ultimately to those generals who would move
seamlessly into their employment on retirement. This is a model that
has since been widely emulated. There is the security industrial com-
plex, whereby corporations and government officials, many also looking
for a lucrative retirement home, have conspired to spend billions of
euros and dollars on ineffective systems of airport security.27 This has
resulted in countless people having their cosmetics, nail files and the
like confiscated while the few people who actually had bombs sailed
straight through, even when they have done everything possible to
draw attention to themselves.28 
But it is now the medical industrial complex that is setting the rules
of the game, by redefining the goals of health care away from those in
most need, such as those with tropical diseases or ageing populations
with chronic disorders and towards those who are essentially well. If
the general practitioner is unwilling to respond to these pressures and
incentives, many others will. In particular, those who do respond are
the many private providers who offer so-called screening services using
ever more complex imaging technology to visualise every part of one’s
body to find entirely harmless anomalies for which they can extract
money for giving what they call ‘treatment’. McCartney catalogues
many examples, such as the treatment of surrogate markers, such as
cholesterol, even at levels far below where it might do any harm, the
creation of new so-called diseases, such as pre-diabetes, and treatment
of raised levels of prostate-specific antigen, even at the cost of often
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appalling side effects while giving no overall benefit.17 Yet at the same
time as people are being encouraged to spend ever greater sums of
money on interventions that are useless, corporations are telling every-
one that the rise in health care expenditure is unaffordable and must
be rationed. Moreover, those same corporations are funding lobby
groups, often in a manner that is far from transparent, to persuade gov-
ernments and the public that the European welfare state is unsustain-
able, using highly selective and frequently misleading evidence. In
some cases, where governments view the economic crisis as a once in
a lifetime opportunity to roll back the welfare state, they are pushing at
an open door.29 
Conclusions
European citizens today are like those who looked around them in
Eastern Europe in 1989 and realised that the systems they inhabited
were being run not for them but for a small elite. These systems were
becoming increasingly dysfunctional and were failing to deliver on
what they had promised. They had to change and they did. Today, it is
equally clear that our systems have to change, but so far they have not.
One of the first things that new public health trainees are taught is
the importance of looking upstream, to the fundamental determinants
of health. To make a difference to population health it is necessary to
tackle the causes of the causes.30 The policies of austerity being pursued
in Europe today are already impacting adversely on health, with rising
suicides and denial of necessary care.6 Yet, as is now increasingly
clear, they are not even doing what they were designed to achieve in
the economy, instead they are choking recovery. As this paper has
shown, many of those who promoted the deregulation of financial mar-
kets are now turning to the social sector as the next big opportunity to
turn a profit. Yet their actions will not help those who need care and
will medicalise the problems, real and imagined, of those who do not
need it. Inevitably, scarce resources that could be used to alleviate gen-
uine suffering will be wasted. 
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